• Company remained under voluntary administration during Q1 2025
• Sale of geneType business completed in Dec 2024 for $625,000
• Cash receipts of $0.485 million, down $1.135 million from prior quarter
• Net cash outflow of $0.73 million during the quarter

Genetic Technologies Limited (ASX: GTG) released its Appendix 4C and Quarterly Activities Report for the quarter ended 31 March 2025. During the quarter, the company remained subject to external administration while the Administrators progressed the sale and recapitalisation process. At the second meeting of creditors held on 27 February 2025, creditors resolved that the company enter into a Deed of Company Arrangement (DOCA), which was subsequently executed on 19 March 2025, with the Administrators continuing as Deed Administrators. The Deed Administrators have continued to progress the implementation of the DOCA and the proposed recapitalisation of the company. The company also completed the sale of its geneType business and assets to Rhythm Biosciences Limited for $625,000 plus GST in December 2024. During the March quarter, the company received $510,000 in proceeds from the disposal of businesses. At the end of March 2025, the company had $0.27 million in cash and cash equivalents. Cash receipts from customers for the quarter of $0.485 million were $1.135 million lower than the prior quarter, as the business was not trading during this period. All cashflows received were residual in nature, arising from the administration process, and did not represent operational trading activity. Net cash flow from all activities during the quarter were a net outflow of $0.73 million, with net outflows from operating activities of $1.241 million partially offset by net cash inflows from investing activities of $0.51 million from net proceeds from the sale of business and assets.